Baxter has received approval for its Amia Automated Peritoneal Dialysis (APD) System with the Sharesource Connectivity Platform from Health Canada.
The AMIA APD and Sharesource system is a renal therapy system which caters to the dialysis therapy needs of Canadians suffering from chronic kidney disease.
Baxter Canada regional head and general manager Stephen Thompson said: ”Baxter’s Amia with Sharesource system is uniquely designed to help more patients self-administer home PD therapy and allow healthcare providers the ability to remotely manage their patients’ care.”
The device has patient-centric features such as voice guidance providing step-by-step instructions, a touchscreen control panel and two-way telemedicine capabilities to support remote patient management.
The Sharesource connectivity platform is integrated into Amia, creating a store-and-forward technology to allow healthcare providers to receive dialysis-related treatment.
Data can then be used to remotely adjust the patients’ home device settings from the clinic while ensuring security.
People suffering from end-stage renal disease (ESRD) require dialysis treatment or a kidney transplant.
Baxter’s PD therapy allows patients to manage the procedure at home. It flushes the blood of toxins and removes extra fluid through the body’s peritoneal cavity.
The device is being used by around 400 ESRD patients in the US and records 13,000 treatments with the Sharesource Connectivity Platform.
